David M. Ashley, MBBS (Hon), FRACP, PhD
Rory David Deutsch Professor of Neuro-Oncology
Dr. Ashley is a distinguished professor in the Departments of Neurosurgery, Pediatrics, Medicine, and Pathology at Duke University. Dr. Ashley is the Director of The Preston Robert Tisch Brain Tumor Center at Duke the largest brain tumor center in North America. His career in cancer research dates more than two decades. His peer-reviewed publication record focuses on CNS tumors is diverse and includes laboratory-based cancer research, clinical trials, as well as public health and psycho-oncology research. His primary research focus is on the immunology, epigenetics, and genetics of brain tumors. His achievements in research have led to change in practice in the care of both children and adults with brain tumors. Dr. Ashley is highly regarded for his work, as evidenced by numerous national grants, awards and invitations to plenary sessions and symposia of international standing.
Publications:
- Clinical trial of feasibility for mindfulness intervention for patients with newly diagnosed high grade glioma
- TIP-25. Randomized phase 2 clinical trial of repeated intratumoral and cervical perilymphatic injections (CPLIs) of lerapolturev vs. lomustine in recurrent glioblastoma (rGBM): safety lead-in results
- TIP-30. Molecularly-guided phase 2 umbrella trial for children and young adults with newly-diagnosed high-grade glioma (HGG) including diffuse intrinsic pontine glioma (DIPG): CONNECT TarGeT (Targeted pediatric HGG therapy) trial in progress
- Lymphotropic Virotherapy Induces DC and High Endothelial Venule Inflammation, Promoting the Antitumor Efficacy of Intratumor Virus Administration Available to Purchase
- STING activation induces cytotoxic and immune responses in meningiomas via inflammatory cell death pathways
- STING-induced blood-brain barrier opening combined with radiotherapy potentiates antitumor response in a high-grade glioma model
- A longitudinal, multi-omic atlas reveals the emergence of a spatially organized immunosuppressive ecosystem in resistant melanoma
- Peptide-based tumor-associated antigen vaccine in glioblastoma: Correlative results of the ETAPA Phase I clinical trial
- IL-12/anti-PD-1 armored oncolytic HSV-1 reprograms CNS immunity: Integrated longitudinal immune, genomic, and metabolic CSF profiling in the MVR-C5252 PuMP Trial
- Spatial immune and vascular remodeling defines recurrence in oligodendroglioma
- Integrative single-nuclei spatial transcriptomic profiling of primary and recurrent human glioblastoma reveals cell-specific EGFRvIII expression and ANXA1 signaling axis
- Endogenous retrovirus-derived neoantigens enable a personalized cancer vaccine strategy for glioblastoma
- Automated imaging response evaluation system: Prototype software tool for standardized radiographic response assessment in glioblastoma clinical trials